MacroGenics (MGNX) closed the sale of its good manufacturing practices drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million, the companies said Thursday.
The transaction includes MacroGenics' manufacturing site and warehouse in Maryland, with Bora also absorbing 140 employees, according to a statement.
Concurrently, the companies said they signed a supply agreement, under which Bora will support process development and drug substance production for MacroGenics' pipeline requirements.
MacroGenics shares rose more than 3% in Thursday trading.
Price: $4.78, Change: $+0.16, Percent Change: +3.35%